Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years.

Bygrave H, Ford N, van Cutsem G, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, Triviño L, Makakole L, Kranzer K.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e75-8. doi: 10.1097/QAI.0b013e3182097505.

PMID:
21164354
2.

Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.

Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, Hilderbrand K, Goemaere E, Vlahakis N, Trivino L, Makakole L, Cleary S.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e68-74. doi: 10.1097/QAI.0b013e31822a9f8d.

PMID:
21765366
3.

Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.

Brennan AT, Shearer K, Maskew M, Long L, Sanne I, Fox MP.

Trop Med Int Health. 2014 May;19(5):490-8. doi: 10.1111/tmi.12285. Epub 2014 Mar 3.

4.

Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.

Brennan AT, Maskew M, Ive P, Shearer K, Long L, Sanne I, Fox MP.

J Int AIDS Soc. 2013 Nov 19;16:18794. doi: 10.7448/IAS.16.1.18794.

5.

Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.

Manosuthi W, Lueangniyomkul A, Mankatitham W, Chimsuntorn S, Tantanathip P, Thongyen S, Suntisuklappon B, Nilkamhang S, Sungkanuparph S.

J Infect. 2011 May;62(5):406-9. doi: 10.1016/j.jinf.2011.02.012. Epub 2011 Mar 5. No abstract available.

PMID:
21382413
6.

Adoption of new HIV treatment guidelines and drug substitutions within first-line as a measure of quality of care in rural Lesotho: health centers and hospitals compared.

Labhardt ND, Sello M, Lejone T, Ehmer J, Mokhantso M, Lynen L, Pfeiffer K.

Trop Med Int Health. 2012 Oct;17(10):1245-54. doi: 10.1111/j.1365-3156.2012.03051.x. Epub 2012 Jul 29.

7.

Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.

Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, Schackman BR, Scott CA, Lu Z, Freedberg KA.

Clin Infect Dis. 2010 Feb 1;50(3):416-25. doi: 10.1086/649884.

8.

[Analysis of adherence and efficiency when replacing an antiretroviral therapy with efavirenz-emtricitabine-tenofovir in a single daily dose].

García-Ramos SE, Santolaya Perrín MR, Fernández-Pacheco García-Valdecasas M.

Farm Hosp. 2012 Sep-Oct;36(5):315-20. doi: 10.1016/j.farma.2011.03.006. Epub 2012 Jul 31. Spanish.

PMID:
22858089
9.

Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.

Njuguna C, Orrell C, Kaplan R, Bekker LG, Wood R, Lawn SD.

PLoS One. 2013 May 22;8(5):e63596. doi: 10.1371/journal.pone.0063596. Print 2013.

10.

Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.

Havens PL, Hazra R.

Pediatr Infect Dis J. 2015 Apr;34(4):406-8. doi: 10.1097/INF.0000000000000650. No abstract available.

11.

A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience.

Rosso R, Parodi A, Torrisi C, De Terlizzi F, Viscoli C, Vignolo M.

AIDS Res Hum Retroviruses. 2010 Dec;26(12):1265-6. doi: 10.1089/aid.2010.0122. Epub 2010 Sep 28. No abstract available.

PMID:
20874420
12.

The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.

Young J, Wang Q, Fux CA, Bernasconi E, Furrer H, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC; Swiss HIV Cohort Study.

HIV Med. 2014 Sep;15(8):505-10. doi: 10.1111/hiv.12149. Epub 2014 Mar 18.

13.

Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.

van Griensven J, Zachariah R, Rasschaert F, Atté EF, Reid T.

Trans R Soc Trop Med Hyg. 2009 Jun;103(6):613-9. doi: 10.1016/j.trstmh.2008.08.015. Epub 2008 Oct 2.

PMID:
18835003
14.

High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.

Bonjoch A, Echeverría P, Perez-Alvarez N, Puig J, Estany C, Clotet B, Negredo E.

Antiviral Res. 2012 Oct;96(1):65-9. doi: 10.1016/j.antiviral.2012.07.009. Epub 2012 Aug 6.

PMID:
22892171
15.

Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.

Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, Bolton-Moore C, Chintu N, Mulenga PL, Stringer EM, Sheneberger R, Mwaba P, Stringer JS.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):63-70. doi: 10.1097/QAI.0b013e3181c6c65c.

16.

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):15-21.

PMID:
12792350
17.

Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.

Calza L, Trapani F, Tedeschi S, Piergentili B, Manfredi R, Colangeli V, Viale P.

Scand J Infect Dis. 2011 Aug;43(8):656-60. doi: 10.3109/00365548.2011.572906. Epub 2011 Apr 1.

PMID:
21453205
18.

The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients.

Wikman P, Safont P, Del Palacio M, Moreno A, Moreno S, Casado JL.

Nephrol Dial Transplant. 2013 Aug;28(8):2073-81. doi: 10.1093/ndt/gft210. Epub 2013 Jun 5.

PMID:
23739150
19.

Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.

[No authors listed]

Prescrire Int. 2004 Oct;13(73):180-2.

PMID:
15499699
20.

High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.

Pérez-Elías MJ, Moreno S, Gutiérrez C, López D, Abraira V, Moreno A, Dronda F, Casado JL, Antela A, Rodríguez MA.

AIDS. 2005 Apr 29;19(7):695-8.

PMID:
15821395

Supplemental Content

Support Center